FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

ORDAN MARK S		 2. Issuer Name and Ticker or Trading Symbol

MEDNAX, INC. [ MD ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Executive Officer
(Last)          (First)          (Middle)

1301 CONCORD TERRACE		 3. Date of Earliest Transaction (MM/DD/YYYY)

3/1/2022
(Street)

SUNRISE, FL 33323
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 3/1/2022  A(1)  76253 A$0.00 313249 (2)D  
Common Stock 3/1/2022  A(3)  76253 A$0.00 389502 D  
Common Stock 3/1/2022  F(4)  20691 D$23.47 368811 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
(1) Restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan"), in connection with an annual equity award. Twenty-five percent (25%) of the restricted shares will vest on March 1, 2023, twenty-five percent (25%) of the restricted shares will vest on March 1, 2024 and fifty percent (50%) of the restricted shares will vest on March 1, 2025, subject to the terms of the Plan.
(2) Includes 28,571 restricted shares granted pursuant to the Plan in connection with achievement in excess of target of specified performance-based criteria for the performance period from January 1, 2021 through December 31, 2021.
(3) Restricted shares granted pursuant to the Plan in connection with an annual equity award. The number of shares being reported represents the "target" number of restricted shares and does not include the right of the reporting person to receive up to 38,127 additional shares based on the achievement of certain performance-based criteria for the twelve months ending December 31, 2022. The actual number of shares earned could be less than or greater than the target number, depending on the level of performance achieved, and all of the restricted shares granted are subject to forfeiture if minimum levels of performance are not met. Any restricted shares earned will not vest any earlier than in three installments of twenty-five percent (25%) on March 1, 2023, twenty-five percent (25%) on March 1, 2024 and fifty percent (50%) on March 1, 2025, subject to the terms of the Plan.
(4) Represents 20,691 restricted shares withheld for payment of taxes upon vesting of shares.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
ORDAN MARK S
1301 CONCORD TERRACE
SUNRISE, FL 33323		X
Chief Executive Officer
Signatures
/s/ Dominic J. Andreano, Attorney-in-Fact3/3/2022
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Pediatrix Medical (NYSE:MD)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Pediatrix Medical Charts.
Pediatrix Medical (NYSE:MD)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Pediatrix Medical Charts.